Physician profile
Alice N Johnson
NPI 1558615419
$8,290.61
in general payments reported to CMS, 2019-2025
23 companies · $2,275 in 2025
The $2,275 reported for 2025 was more than what 96% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,202 · 2022: $1,342 · 2023: $1,940 · 2024: $1,531 · 2025: $2,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,746.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,206.21 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $2,280.71 | 2021-2025 | Epclusa, Biktarvy |
| Merck Sharp & Dohme LLC | $616.67 | 2021-2025 | Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $259.18 | 2021-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $241.87 | 2021-2025 | Invega Sustenna |
| Janssen Products, Lp | $219.47 | 2021-2023 | Symtuza |
| Abbvie INC. | $151.29 | 2022-2025 | |
| Shionogi INC | $128.00 | 2024-2025 | Fetroja |
| Genzyme Corporation | $126.31 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $124.74 | 2024 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $123.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $113.40 | 2025 | Uzedy |
| Emd Serono, INC. | $102.90 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.44 | 2024-2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $96.23 | 2021-2024 | Mytesi |
| Theratechnologies INC. | $75.35 | 2021-2025 | Egrifta, Trogarzo |
| Lilly USA, LLC | $69.60 | 2023-2024 | Mounjaro |
| Janssen Scientific Affairs, LLC | $36.59 | 2023 | Symtuza |
| Axsome Therapeutics, INC. | $27.68 | 2024 | Auvelity |
| Exact Sciences Corporation | $25.35 | 2024 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $24.36 | 2024 | Kimyrsa, Rezzayo |
| Lundbeck LLC | $14.19 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.